| ARCA Exchange | US Country |
The company specializes in investment strategies that focus primarily on American Depositary Receipts (ADRs) for Novo Nordisk A/S (B Shares). Under typical market conditions, the investment series commits at least 95% of its net assets to these ADRs. It's important to note that the fund does not make direct investments in Novo Nordisk itself and operates as a non-diversified fund, meaning its holdings are concentrated in fewer securities rather than being spread across a wide array of investments.
The primary service offered is investing in American Depositary Receipts (ADRs) of Novo Nordisk A/S (B Shares). This approach allows investors to gain exposure to the shares of Novo Nordisk while primarily trading in ADR format, which can simplify the logistics of international trading and ownership.
The fund’s non-diversified structure enables focused investments in Novo Nordisk, creating potential for higher growth by not spreading assets over a wide range of companies. This concentrated investment strategy is designed for investors who have a strong belief in the performance of Novo Nordisk and prefer to capitalize on that singular opportunity.